Skip to content
The Policy VaultThe Policy Vault

Skyrizi subcutaneous — Medica

All inflammatory conditions listed in standard criteria

Initial criteria

  • Patient meets the standard Inflammatory Conditions – Skyrizi Subcutaneous Prior Authorization Policy criteria

Reauthorization criteria

  • Patient continuing therapy meets the standard Inflammatory Conditions – Skyrizi Subcutaneous Prior Authorization Policy criteria

Approval duration

initial therapy as directed or 1 year for continuing therapy